This site is intended for healthcare professionals
Transplantation webinar on demand banner
Transplantation Learning Zone
Declaration of sponsorship Novartis Pharma AG

2021 Webinar Highlights

Declaration of sponsorship Novartis Pharma AG
Read time: 25 mins
Last updated:1st Mar 2022
Published:1st Mar 2022

In our recent webinar streamed live during March 2021, Professor Julio Pascual, Professor Stefan Berger, Professor Helio Tedesco Silva Junior and Dr Olivier Aubert considered: 

  • Living without calcineurin inhibitors (CNIs) 
  • The future use of iscalimab 
  • Future biomarkers for CNI withdrawal or limitation 
  • The future of iBox, and more. 

Navigate to the specific Q&A session, including patient case study, using the quick links below.

Launch our EACCME® accredited eLearning module on Achieving long-term outcomes in renal transplantation to receive 1 European CME credit (ECMEC®)

Q&A session 1

Question 1: Can we live without CNIs? 00:00-00:58

Question 2: Is CNI-free immunosuppression a good option following the first months after transplantation or at the very beginning in de novo patients? Will iscalimab be a good option for a co-stimulation blockade? 00:59-02:33

Question 3: What should we do in the future when using iscalimab? 02:34-03:37

Question 4: Are there any more drugs in the pipeline or is the real hope for iscalimab? Is there any idea about good development of these drugs beyond phase 3, and how can this development be delivered? 03:38-06:53

Question 5: Is there a biomarker for CNI withdrawal or for CNI limitation? 06:54-09:00

Question 6: Given that the FDA said no to using the iBox as a primary endpoint, what are the next steps of developing the iBox to ensure we have it onboard for predicting really hard outcomes? 09:01-10:34

Question 7: Regarding PROMs, are we measuring what the patient wants and believes about transplantation or are we relying on other things that the patient might not care about at all? 10:35-end

Q&A session 2

Question 1: Can we live without CNIs? 00:00-01:54

Question 2: The belatacept trials have been showing good long-term results but how is it that almost no one is using it in de novo patients? Should we add new co-stimulatory blockers in the pipeline of the patients? 01:55-03:11

Question 3: Will iscalimab, if approved, offer patients better options for longer outcomes and transplant success? 03:12-04:37

Question 4: What is your experience on tacrolimus minimisation or even the TRANSFORM regime on low TAC and everolimus in patients? 04:38-07:00

Question 5: Is there a biomarker to remove or deeply minimise tacrolimus? 07:01-08:05

Question 6: How is the impact of iBox conceived in the practice and how can the algorithm be used? 08:06-09:55

Question 7: Is there any news about the pipeline of drugs that lies ahead? 09:56-11:37

Question 8: Are we measuring the variables that we should be measuring? Should we be relying more on patient-related outcome measurements to see how the patient feels and thinks about it? 11:38-end

Patient case study

This case study considers the management of a patient requiring renal transplantation. A 62-year-old male patient with CDK demonstrated nephroangiosclerosis and started haemodialysis in 2013. Co-morbidities included hypertension, mild dyslipidemia and the patient was overweight, with a BMI of 29 mg/m2. The patient had a PRA of 0% and had been on the transplantation waiting list since 2013, before a deceased donor became available for him in 2015. 

The donor was a 68-year-old male with cerebral haemorrhage and brain death, who had mild diabetes, hypertension and an SCr of 1.2 mg/dl. Here our faculty explore the possibilities for immunosuppression for the transplantation recipient.

If you want to learn more about Transplantation, visit our Transplantation Learning Zone where you can explore even more about the management of transplant patients and learn about existing regimens through to the latest targeted treatments available.